Stockscreener 앱 받기
2.47
0.40%
-0.010
시장 영업 전:
2.47
전일 마감가:
$2.48
열려 있는:
$2.51
하루 거래량:
218.96K
Relative Volume:
0.95
시가총액:
$139.61M
수익:
$26.03M
순이익/손실:
$-17.12M
주가수익비율:
-2.4794
EPS:
-0.9962
순현금흐름:
$-24.53M
1주 성능:
+2.92%
1개월 성능:
-17.39%
6개월 성능:
+46.59%
1년 성능:
+212.66%
1일 변동 폭
$2.4299
$2.59
1주일 범위
$2.3348
$2.60
52주 변동 폭
$0.70
$3.82
코넥트 바이오파마 Stock (CNTB) Company Profile
명칭
Connect Biopharma Holdings Ltd
전화
858-727-1040
주소
3580 CARMEL MOUNTAIN ROAD, SUITE 200, SAN DIEGO
Compare CNTB vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CNTB
Connect Biopharma Holdings Ltd
|
2.47 | 139.61M | 26.03M | -17.12M | -24.53M | -0.9962 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
코넥트 바이오파마 Stock (CNTB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-01 | 개시 | Lake Street | Buy |
| 2025-10-31 | 개시 | BTIG Research | Buy |
| 2025-06-12 | 개시 | H.C. Wainwright | Buy |
| 2024-03-04 | 개시 | H.C. Wainwright | Buy |
| 2021-04-13 | 개시 | Jefferies | Buy |
| 2021-04-13 | 개시 | Piper Sandler | Overweight |
| 2021-04-13 | 개시 | SVB Leerink | Outperform |
모두보기
코넥트 바이오파마 주식(CNTB)의 최신 뉴스
BML Capital Management LLC Sells 858,613 Shares of Connect Biopharma Holdings Limited Sponsored ADR $CNTB - MarketBeat
Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
CNTB Stock Price, Quote & Chart | CONNECT BIOPHARMA HOLDINGS L (NASDAQ:CNTB) - ChartMill
Northland Securities Weighs in on CNTB Q1 Earnings - MarketBeat
Connect Biopharma asthma, COPD trials to continue as planned By Investing.com - Investing.com India
CNTB SEC FilingsConnect Biopharma Holdings Ltd 10-K, 10-Q, 8-K Forms - Stock Titan
Connect Biopharma asthma, COPD trials to continue as planned - Investing.com
Connect Biopharma Continues Phase 2 Seabreeze STAT Trials for Rademikibart in Asthma and COPD with Topline Data Expected Mid-2026 - Minichart
Connect Biopharma: DMC clears interim analysis; Phase 2 Seabreeze STAT enrollment to continue - TradingView
Connect Biopharma (NASDAQ: CNTB) DMC backs Seabreeze STAT trials, topline data mid-2026 - Stock Titan
Interim review leaves asthma, COPD drug studies unchanged ahead of mid-2026 data - Stock Titan
Connect Bio (CNTB) Stock: Market Efficiency (At Highs) 2026-04-20Trending Picks - Cổng thông tin điện tử tỉnh Lào Cai
CNTB | Connect Biopharma Holdings Limited Insider Trading - Quiver Quantitative
Connect Biopharma Holdings (CNTB) insider-linked stake of 9.6% disclosed - Stock Titan
Q1 Earnings Estimate for CNTB Issued By HC Wainwright - MarketBeat
Is Connect Bio (CNTB) Stock Consolidating | Price at $2.69, Up 2.28%Expert Stock Picks - Cổng thông tin điện tử Tỉnh Sơn La
Director at Connect Biopharma (CNTB) takes shares instead of cash pay - Stock Titan
[Form 4] Connect Biopharma Holdings Ltd Insider Trading Activity - Stock Titan
Connect Biopharma (NASDAQ:CNTB) Director James Huang Acquires 1,160,000 Shares - MarketBeat
Entity tied to CNTB director James Huang buys 1.16M shares in open market - Stock Titan
Connect Biopharma (NASDAQ: CNTB) holder Panacea adds 1.16M shares - Stock Titan
Connect Biopharma (NASDAQ:CNTB) Posts Quarterly Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat
ETFs Investing in Connect Biopharma Holdings Ltd. Stocks - TradingView — Track All Markets
Connect Biopharma Holdings Ltd reports results for the quarter ended December 31Earnings Summary - TradingView
Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update - The Manila Times
Rademikibart drives Connect Biopharma (NASDAQ: CNTB) asthma and COPD strategy - Stock Titan
[8-K] Connect Biopharma Holdings Ltd Reports Material Event - Stock Titan
Connect Biopharma (NASDAQ:CNTB) Receives "Buy" Rating from BTIG Research - MarketBeat
BTIG Reiterates Buy Rating on Connect Biopharma Hldgs (CNTB) | C - gurufocus.com
BTIG reiterates Buy on Connect Biopharma stock after Phase 1 data - Investing.com Australia
BTIG reiterates Buy on Connect Biopharma stock after Phase 1 data By Investing.com - Investing.com South Africa
Connect Biopharma Announces Positive Phase 1 Results for IV Rademikibart, Showing Rapid Lung Function Improvement in Asthma and COPD Patients - Minichart
Connect Biopharma and Bimergen Energy Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Green Bay Press-Gazette
Connect Biopharma touts rapid IV rademikibart FEV1 gains; Phase 3 atopic dermatitis data impresses - MarketBeat
Connect Biopharma reports positive Phase 1 data for asthma drug By Investing.com - Investing.com Australia
Connect Biopharma raises $20.2 million in private placement By Investing.com - Investing.com South Africa
Connect Biopharma stock jumps on positive drug trial results By Investing.com - Investing.com India
Connect Biopharma Announces $20.2 Million Private Placement Financing - Bitget
Connect Biopharma raises $20.2 million in private placement - Investing.com
Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPD - Bitget
Connect Biopharma Raises $20.2 Million in Private Placement of 6.13 Million Shares at $3.25 - TradingView
Connect Biopharma reports positive Phase 1 data for asthma drug - Investing.com
Connect Biopharma (NASDAQ: CNTB) nets $20.2M and reports promising rademikibart results - Stock Titan
Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study - GlobeNewswire
Connect Biopharma Announces Positive Topline Data from its - GlobeNewswire
Connect Biopharma (CNTB) Expected to Announce Earnings on Monday - MarketBeat
코넥트 바이오파마 (CNTB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.14%
0.48%
자본화:
|
볼륨(24시간):